ArticleCancer immunology, immunotherapy : CII2021

Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors.

Kyriakos P Papadopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.